Research progress of scoring system in diagnosis and treatment of peritoneal metastatic carcinoma

doi:10.3877/cma.j.issn.2095-3224.2023.01.011

Abstract

Abstract:

Peritoneal metastasis is the advanced stage of the tumor and the prognosis is poor. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) can significantly improve the prognosis of patients. The prognosis of patients is often related to the severity of peritoneal disease and the degree of tumor cell depletion in CRS. There are various scoring systems to reasonably assess the peritoneal tumor burden before and during operation. This article reviews the scoring systems in the diagnosis and treatment of peritoneal metastatic cancer.

Key words: Colorectal neoplasms, Neoplasm metastasis, Peritoneal neoplasms, Peritoneal metastasis, The severity of peritoneal disease, Scoring system, Peritoneal cancer index, Prognosis

Zhijie Wu, Zixu Yuan, Jian Cai, Jia Ke, Hui Wang. Research progress of scoring system in diagnosis and treatment of peritoneal metastatic carcinoma[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(01): 75-78.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2023.01.011

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2023/V12/I01/75

References 41

[1]	Delia CG, Martin H, Mohammad A, et al. Primary and metastatic peritoneal surface malignancies [J]. Nat Rev Dis Primers, 2021, 7(1): 92.
[2]	Sugarbaker PH. Peritonectomy procedures [J]. Ann Surg, 1995, 221(1): 29-42.
[3]	马茹, 姬忠贺, 张颖, 等. 胃肠道癌腹膜转移的核心病理机制 [J]. 中华胃肠外科杂志, 2021, 24(3): 198-203.
[4]	Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer [J]. Br J Surg, 2002, 89(12): 1545-1550.
[5]	Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer [J]. Ann Surg Oncol, 2001, 8(8): 632-637.
[6]	Sugarbaker PH. Carcinoma of the colon--prognosis and operative choice [J]. Curr Probl Surg, 1981, 18(12): 753-802.
[7]	Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer [J]. J Clin Oncol, 2003, 21(20): 3737-3743.
[8]	Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer[J]. Ann Surg Oncol, 2008, 15(9): 2426-2432.
[9]	Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study [J]. J Clin Oncol, 2004, 22(16): 3284-3292.
[10]	Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial [J]. The Lancet Oncology, 2021, 22(2): 256-266.
[11]	Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial [J]. Ann Surg Oncol, 2011, 18(6): 1575-1581.
[12]	Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study [J]. Ann Surg Oncol, 2015, 22(5): 1570-1575.
[13]	Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy [J]. J Clin Oncol, 2003, 21(24): 4560-4567.
[14]	李雁. 腹膜癌研究之我见 [J]. 中国肿瘤临床, 2012, 39(22): 1685-1686.
[15]	李雁, 周云峰, 梁寒, 等. 细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识 [J]. 中国肿瘤临床, 2015, 42(4): 198-206.
[16]	Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study [J]. J Clin Oncol, 2003, 21(5): 799-806.
[17]	Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis [J]. Cancer Treat Res, 1996, 82: 359-374.
[18]	Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy [J]. Ann Surg Oncol, 1999, 6(8): 727-731.
[19]	Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy [J]. Ann Surg Oncol, 2010, 17(5): 1330-1336.
[20]	von Breitenbuch P, Boerner T, Jeiter T, et al. Laparoscopy as a useful selection tool for patients with prior surgery and peritoneal metastases suitable for multimodality treatment strategies [J]. Surg Endosc, 2018, 32(5): 2288-2294.
[21]	Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer [J]. Int Semin Surg Oncol, 2005, 2(1): 3.
[22]	Yong ZZ, Tan GHC, Shannon N, et al. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) [J]. World J Surg Oncol, 2019, 17(1): 138.
[23]	Sugarbaker H.P., 杨智冉, 李雁. 国际腹膜癌治疗指南:肿瘤细胞减灭术加腹腔化疗临床路径 [J]. 中国肿瘤临床, 2020, 47(11): 541-551.
[24]	Nelson RC, Chezmar JL, Hoel MJ, et al. Peritoneal carcinomatosis: preoperative CT with intraperitoneal contrast material [J]. Radiology, 1992, 182(1): 133-138.
[25]	Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer [J]. Radiology, 2002, 223(2): 495-499.
[26]	Koh JL, Yan TD, Glenn D, et al. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis [J]. Ann Surg Oncol, 2009, 16(2): 327-333.
[27]	Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study [J]. J Surg Oncol, 2010, 102(6): 565-570.
[28]	Goéré D, Sourrouille I, Gelli M, et al. Peritoneal metastases from colorectal cancer: treatment principles and perspectives [J]. Surg Oncol Clin N Am, 2018, 27(3): 563-583.
[29]	Dresen RC, De Vuysere S, De Keyzer F, et al. Whole-body diffusion-weighted MRI for operability assessment in patients with colorectal cancer and peritoneal metastases [J]. Cancer Imaging, 2019, 19(1): 1.
[30]	Pestieau SR, Sugarbaker PH. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management [J]. Diseases of the Colon and Rectum, 2000, 43(10): 1341-1346.
[31]	Pfannenberg C, Königsrainer I, Aschoff P, et al. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [J]. Ann Surg Oncol, 2009, 16(5): 1295-1303.
[32]	Yuan Z, Xu T, Cai J, et al. Development and validation of an image-based deep learning algorithm for detection of synchronous peritoneal carcinomatosis in colorectal cancer [J]. Ann Surg, 2022, 275(4): e645-e651.
[33]	Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer [J]. Cancer Chemother Pharmacol, 1999, 43 (Suppl): S15-S25.
[34]	Maillet M, Glehen O, Lambert J, et al. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study [J]. Ann Surg Oncol, 2016, 23(3): 863-869.
[35]	Swellengrebel HAM, Zoetmulder FAN, Smeenk RM, et al. Quantitative intra-operative assessment of peritoneal carcinomatosis - a comparison of three prognostic tools [J]. Eur J Surg Oncol, 2009, 35(10): 1078-1084.
[36]	Goéré D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study [J]. Ann Surg Oncol, 2015, 22(9): 2958-2964.
[37]	Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread [J]. Cancer Metastasis Rev, 2003, 22(4): 465-472.
[38]	Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy [J]. Ann Surg, 1995, 221(2): 124-132.
[39]	Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis [J]. Cancer, 2000, 88(11): 2512-2519.
[40]	Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study [J]. Cancer, 2000, 88(2): 358-363.
[41]	Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy [J]. Br J Surg, 2004, 91(6): 739-746.

Please choose a citation manager

Content to export